Pharmacorp Rx closes $23-million bought deal offering

Executive Summary

• Pharmacorp Rx Inc. has closed a C$23 million bought deal public offering, raising aggregate gross proceeds of approximately $23.0 million through the sale of 54,855,000 units.
• The offering was co-led by Canaccord Genuity Corp. and Acumen Capital Finance Partners Ltd., with Raymond James Ltd., iA Private Wealth Inc., and Bloom Burton Securities Inc. participating as underwriters.
• Net proceeds are designated for future acquisition opportunities and general working capital requirements, with no change of control or new insiders created.

Key Details

• Gross Proceeds: Approximately $23.0 million.
• Units Sold: 54,855,000 units.
• Price Per Unit: 42 cents CAD.
• Underwriters: Co-led by Canaccord Genuity Corp. and Acumen Capital Finance Partners Ltd.; included Raymond James Ltd., iA Private Wealth Inc., and Bloom Burton Securities Inc.
• Overallotment: The gross proceeds include the full exercise of the overallotment option.
• Unit Composition: Each unit consists of one common share and one-half of one common share purchase warrant.
• Warrant Terms:
  • Each whole warrant entitles the holder to acquire one common share.
  • Exercise Price: 50 cents per common share.
  • Expiration Date: November 12, 2027.
  • Listing: Conditional approval received for TSX Venture Exchange under symbol PCRX.WT; subject to final acceptance.
• Use of Proceeds: Future acquisition opportunities and general working capital requirements.
• Related Party Transactions:
  • Directors and officers purchased an aggregate of 3,762,010 units.
  • Exemptions from related party policies were utilized under MI 61-101 Sections 5.5(b) and 5.7(a).
  • No new insiders were created, and no change of control occurred.
• Underwriter Compensation:
  • Cash Commission: 6.0% of gross proceeds (3.0% for president's list purchasers; 0% for certain insiders), totaling $1,134,633.
  • Broker Warrants: 2,026,130 broker warrants issued.
  • Broker Warrant Terms: Exercisable up to November 12, 2026, to acquire one unit at an exercise price of 42 cents per unit.
• Regulatory Filings: Offered via prospectus supplement dated November 7, 2025, to the short form base shelf prospectus dated October 14, 2025.

Notable Quotes

• None provided in the text.